文献速递浆细胞疾病

既往单克隆丙种球蛋白病诊断对新诊断多发性骨髓瘤结局的影响

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
PubMed 文献 · Leukemia · 2019-02-20

该研究比较了1973至2015年间本院数据库中既往诊断为MGUS、SMM或SPC的多发性骨髓瘤患者(病例组774例)与按诊断年份1:2匹配的无已知MG患者(对照组1548例)。中位随访81个月后,病例组中位OS长于对照组(71个月 vs 56个月),OS改善仅限于既往SMM(80个月)和SPC(95个月)患者,而MGUS为60个月。多因素分析显示既往MG与较低的全因死亡率相关,且仅限于既往SMM/SPC组(HR 0.68,95%CI 0.50-0.93),MGUS组未达统计学显著(HR 0.83,95%CI 0.66-1.05)。

要点

  • 既往MG(SMM/SPC)的新诊断MM患者中位OS长于无已知MG者(71个月 vs 56个月)。
  • OS改善限于既往SMM(80个月)和SPC(95个月),MGUS为60个月。
  • 既往SMM/SPC组全因死亡风险低于对照组(HR 0.68,95%CI 0.50-0.93),MGUS组未达统计学显著。

核心结论

  • 有既往MG诊断的MM患者OS优于无已知MG者,但获益仅限于既往SMM或SPC患者。

研究设计与样本

  • 从本院数据库识别1973至2015年既往诊断为MGUS、SMM或SPC的MM患者(病例组774例),与按诊断年份1:2匹配的无已知MG患者(对照组1548例)比较。

主要发现

  • 中位随访81个月,病例组中位OS为71个月,对照组为56个月。
  • 既往SMM患者中位OS为80个月,SPC为95个月,MGUS为60个月。
  • 多因素分析显示既往SMM/SPC组全因死亡风险低于对照组(HR 0.68,95%CI 0.50-0.93),MGUS组未达统计学显著(HR 0.83,95%CI 0.66-1.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution's database and compared to those without a known MG (controls). The primary outcome of interest was overall survival (OS). Multivariate analysis was performed to ascertain factors impacting all-cause mortality. We identified 774 patients with a prior diagnosis of MGUS, SMM or SPC (cases) and a control population (1:2) matched for the year of diagnosis (n = 1548). After a median follow-up of 81 months, the cases showed a longer median OS than the controls (71 months vs. 56 months). The improved OS was limited to those with a known prior diagnosis of SMM (80 months) and SPC (95 months), compared to MGUS (60 months). Multivariable analysis revealed that MM patients with known prior MG had less overall mortality than those without, and this was limited to prior SMM/SPC group (HR 0.68, 95% CI: 0.50-0.93), as compared to the MGUS group (HR 0.83, 95% CI: 0.66-1.05).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Goyal G, Rajkumar SV, Lacy MQ, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019. PMID: 30787429. doi:10.1038/s41375-019-0419-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。